LTRN
Lantern Pharma Inc.
Biotechnology · Healthcare · United States
0.66
close · 2026-10-30
value
1
cheaper than peers1
quality
34
stronger fundamentals34
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 7.65× | 21 |
| earnings yield, 3 years ago | -198.2% | 21 |
| earnings yield, 2 years ago | -222.5% | 16 |
| cash flow yield, 3 years ago | -129.6% | 9 |
| cash flow yield, 2 years ago | -145.6% | 9 |
| cash flow yield, 1 year ago | -180.6% | 8 |
| cash flow yield, latest year | -158.9% | 7 |
| earnings yield, latest year | -237.6% | 6 |
| earnings yield, 1 year ago | -292.1% | 6 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.7% | 60 |
| operating margin | 0.0% | 50 |
| return on equity | -157.4% | 18 |
3 of 4 measures available
Facts
| market cap | $10M |
| free cash flow | -$9.0M |
| employees | 16 |
| first trade | 2020-06-11 |
| next earnings | 2026-08-14 |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.57 | -1.93 | -1.47 | -1.31 |
| free cash flow | -$15.7M | -$17.8M | -$14.4M | -$12.8M |
| net income | -$17.1M | -$20.8M | -$16.0M | -$14.3M |
| revenue | $0 | $0 | $0 | $0 |